Reduce Dose, or Discontinue Biologics for Patients with Low RA Disease Activity: Report
To read the full story
Related Article
- MHLW’s New Anti-RA Measures Likely to Push Proper Use of Pricy Biologics
June 11, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
- MHLW Proposes Discussing Proper Use of High-Cost Biologics in Preparation for Revision of RA Measures
April 27, 2018
- MHLW’s Panel to Discuss First Revision of Anti-RA Measures in 7 Years; Proper Use of Biologics to Be a Focus
March 28, 2018
REGULATORY
- Japan Pharma Subgroup Talks to Feed into Pricing, Budget Debates
November 16, 2026
- Japan Names 38 Top-Rated Generic Makers for Stable Supply
November 16, 2026
- Pharma Calls for Drug Price Hikes, Govt Purchases to Spur MCM Investment
November 16, 2026
- Stable Supply Drives Japan’s Generic Drug Delistings: Jiho Tally
November 16, 2026
- Optimal Use Guidelines Issued for Vyepti; Updates for Leqembi, Kisunla, Keytruda
November 13, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





